



GEDEON RICHTER



**Richter and HRA Pharma  
Agreement on Intellectual Property Rights of Esmya®  
in respect of Latin America**

29 May 2014

BUDAPEST and PARIS – Gedeon Richter Plc. ('Richter') and Laboratoire HRA Pharma ('HRA Pharma') today announced that they concluded a sale and purchase agreement in connection with intellectual property rights of ulipristal acetate for the treatment of benign gynaecological disorders with respect to the territories of Latin America. No financial terms related to the agreement were disclosed.

Following the acquisition of PregLem and its innovative product Esmya® in late 2010, Watson Pharmaceuticals, Inc. received exclusive licensing rights to develop and market Esmya® in the USA and in Canada. In December 2011, Richter obtained from HRA Pharma an extension of its geographical scope for Esmya® to the CIS and China, two key markets with a significant growth potential. In June 2013 Richter and HRA Pharma entered into a licensing agreement in connection with marketing rights of ulipristal acetate related to the Latin American region.

"This transaction is considered to be a further strategic move to strengthen Richter's direct position in Latin America and at the same time to become gradually a global female healthcare player", said Erik Bogsch, Managing Director of Richter.

CEO of HRA Pharma, Erin Gainer added "This new agreement adds a new dimension to our partnership with Richter and marks our common will to foster access to all women, whatever their geographic location, to best in class medicines."

**For further information:**

**Richter:**

Katalin Ördög, Investor Relations +36 1 431 5680

Zsuzsa Beke, Public Relations +36 1 431 4888

**HRA Pharma:**

Karina Gajek +33 1 40 33 66 02

**About Gedeon Richter Plc**

Gedeon Richter Plc. ([www.richter.hu](http://www.richter.hu)) headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Richter's consolidated sales were approximately EUR 1.2 billion (USD 1.6 billion) while its market capitalization amounted to EUR 2.8 billion (USD 3.8 billion) in 2013. The product portfolio of the Company covers almost all important therapeutic areas, including gynaecology, central nervous system, and cardiovascular. Having the largest R&D unit in Central Eastern Europe, the Company's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the female healthcare field worldwide. Richter is also active in the scope of biosimilar product development

**About Laboratoire HRA Pharma**

HRA Pharma, UPA licensor, still retains worldwide rights to the molecule for the treatment of benign gynaecological disorders including uterine myoma; the company is looking for marketing and distribution partners in parts of Asia, Australia, New Zealand, Turkey, Middle East and Africa. HRA Pharma is a specialty pharmaceutical company that designs products, devices and supporting services in niche areas of health and makes them available to doctors and patients worldwide. The company targets therapeutic gaps in the areas of reproductive health and endocrinology, and uses innovative marketing solutions and socially-conscious programs, such as contraception education in developing countries, to promote healthy management of drugs and diseases. Headquartered in Paris (France) and with subsidiaries throughout Western Europe, HRA Pharma has built a strong network of R&D, manufacturing, distribution and NGO partners which enables it to satisfy critical patient needs and improve patient health in over 50 countries across the globe.

Visit [www.hra-pharma.com](http://www.hra-pharma.com) for more information.